Quantcast
Last updated on April 16, 2014 at 13:29 EDT

Latest CSL Limited Stories

2013-04-30 12:27:15

Kcentra(TM) Is the First FDA-Approved 4-Factor Prothrombin Complex Concentrate for Warfarin Reversal in the U.S. KING OF PRUSSIA, Pa., April 30, 2013 /PRNewswire/ -- CSL Behring announced today that the U.S. Food and Drug Administration (FDA) approved Kcentra(TM) (Prothrombin Complex Concentrate [Human]), the first non-activated 4-factor prothrombin complex concentrate (PCC) for the urgent reversal of acquired coagulation factor deficiency induced by vitamin K antagonist (e.g.,...

2013-04-16 08:29:59

Expanded label approved in 23 European countries for treatment and pre-procedure prevention of acute episodes of hereditary angioedema MARBURG, Germany, April 16, 2013 /PRNewswire/ -- CSL Behring today announced that European health authorities have approved an extended use of Berinert®, a C1-esterase inhibitor (C1-INH) concentrate, for pre-procedure prevention (short-term prophylaxis) of acute episodes of hereditary angioedema (HAE), in adult and pediatric patients undergoing...

2013-04-16 08:28:59

MONROVIA, Calif. and MELBOURNE, Australia, April 16, 2013 /PRNewswire/ -- Xencor, Inc. announced today that Xencor and CSL Limited have entered into a technology license agreement to provide CSL access to Xencor's Xtend technology to optimize the performance of CSL's monoclonal antibodies. Under the agreement CSL will be granted an exclusive license to utilize Xencor's proprietary Xtend(TM) half-life extension technology in its program against an undisclosed target. Xencor will receive an...

2013-04-03 08:27:56

CSL Behring initiates first "installment" of renewed 3-year commitment to WFH to donate coagulation factor to the WFH Global Alliance for Progress program KING OF PRUSSIA, Pa., April 3, 2013 /PRNewswire/ -- As part of its ongoing commitment to the global coagulation disorders community, CSL Behring will again donate factor product to the World Federation of Hemophilia (WFH) in connection with World Hemophilia Day this month. The medicine will be used in treating patients in...

2013-03-25 12:24:25

DUBLIN, Ireland, March 25, 2013 /PRNewswire/ -- Research and Markets announces the addition of "Global Blood Plasma Market Report: 2013 Edition [http://www.researchandmarkets.com/research/kwh5wb/global_blood ]" to its catalogue. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) With the swift progression in the field of biomedical/healthcare technology, companies operating in the healthcare/pharmaceutical/therapeutic industry are now surmounting in the...

2013-02-28 08:31:17

Label broadened to include the peri-operative management of surgical bleeding in adult and pediatric patients with congenital factor XIII deficiency KING OF PRUSSIA, Pa., Feb. 28, 2013 /PRNewswire/ -- CSL Behring announced today that the U.S. Food and Drug Administration (FDA) has approved an expansion of the indication for Corifact(®), Factor XIII Concentrate (Human), to include the peri-operative management of surgical bleeding in adult and pediatric patients with congenital...

2013-02-21 08:34:03

KING OF PRUSSIA, Pa., Feb. 21, 2013 /PRNewswire/ -- CSL Behring today announced that the United States Food and Drug Administration has approved a 40 g (400 mL) vial size for Privigen®, immune globulin intravenous [human]. The new vial size will simplify preparation and administration of the product when high volumes of it are required. Privigen is approved for the treatment of patients with primary immunodeficiency (PID), a group of rare and serious diseases of the immune system, and...

2013-01-30 08:30:15

KING OF PRUSSIA, Pa., Jan. 30, 2013 /PRNewswire/ -- CSL Behring announced today that it has awarded $78,750 in Local Empowerment for Advocacy Development (LEAD) grants to patient advocacy organizations in New York and Ohio, and to the American Plasma Users Coalition (APLUS). LEAD grants are intended to help local patient organizations achieve their advocacy objectives by further developing an existing initiative or creating a new one. (Logo:...

2013-01-21 08:24:57

KING OF PRUSSIA, Pa., Jan. 21, 2013 /PRNewswire/ -- CSL Behring has announced that the first patient has been enrolled in the pivotal pediatric phase III study to evaluate the safety, efficacy and pharmacokinetics of recombinant fusion protein linking coagulation factor IX with recombinant albumin (rIX-FP) in previously treated children (up to age 11 years). The study site for this first enrollment is the Czech Republic. "CSL continues to advance at a very encouraging rate with our...

2013-01-21 08:24:55

KING OF PRUSSIA, Pa., Jan. 21, 2013 /PRNewswire/ -- Treatment with albumin reduces renal impairment and mortality in cirrhotic patients with spontaneous bacterial peritonitis (SBP), one of the most common bacterial infections in this patient population, according to a new meta-analysis supported by CSL Behring and published today in Clinical Gastroenterology and Hepatology, the official clinical practice journal of the American Gastroenterological Association Institute. Albumin, a natural...